Navigation Links
Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
Date:7/8/2009

CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

"We are extremely pleased with the outcome of this initial clinical study with FX125L," said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. "The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L."

About Funxional Therapeutics Ltd.

Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.

For more information about FXT, please visit our web site (http://www.funxionaltherapeutics.com) or contact us by e-mail (info@funxionaltherapeutics.com).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective int
'/>"/>

SOURCE Funxional Therapeutics Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
4. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
5. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
6. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
9. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
10. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - Portage Biotech ... Exchange: PBT.U), is pleased to announce that its three ... of Portage, who advanced $ 100,000 each in July ... have their Notes and related Coupons converted into 3,500,001 ... and carried 5% coupon. Both the Note and the ...
(Date:9/29/2014)... 2014 Research and Markets  has announced ... Analyzer, and Gas Chromatograph Market by Type , Technology, ... Trends & Forecast to 2013 - 2020" report ... is a process analytical instrument that provides chemical composition ... the way by which companies carry out their production ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), ... technologies and products for advanced microarray diagnostics, is pleased ... to Chairman of the Board of Directors of SQI, ... to serve as a Director on the Board and ... "We are very pleased to have Mr. ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... Inc. announced today the initiation of a Phase ... inhibitor CX-4945 in patients with multiple myeloma. Cylene ... million financing with participation from existing investors including ... Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. ...
... GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK, ... www.helixlife.com ), a private label distribution partnership serving the ... CEO, stated, "HelixLife gives GeneLink reach into new areas ... have not been available to us.  The HelixLife team ...
... and BRUSSELS, Sept. 24 Tarsa Therapeutics, Inc. ... UGNE ) today reported preclinical data showing ... with other drugs in reducing the collagen degradation ... at the 2010 Osteoarthritis Research Society International (OARSI) ...
Cached Biology Technology:Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 2Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 3GeneLink Announces HelixLife Private Label Distribution Agreement 2Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 2Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 3Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 4Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis 5
(Date:9/30/2014)... available in German . ... most expensive foods in the world. Because they grow underground, ... the distinctive smell of truffles is not only of interest ... the direction of the Goethe University Frankfurt have discovered that ... bacteria which are trapped inside truffle fruiting bodies. , White ...
(Date:9/30/2014)... involving mice and published in the October 2014 issue ... , suggests that just because you can do it, ... of Italian scientists have found that using marijuana in ... system. This damage may result in autoimmune diseases and ... disease and rheumatoid arthritis in adulthood. , "I hope ...
(Date:9/30/2014)... your doctor to know what goes wrong with your muscles ... to know what "normal" actually is. That,s where a new ... FASEB Journal comes in. In the ... set of molecules that can help scientists "see" which genes ... more, they found never-before-detected gene activity and that men have ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Scientists identify which genes are active in muscles of men and women 2
... was only something that was necessary to keep your car ... and animals living in cold climates have natural antifreeze proteins ... matter. Without such antifreeze, living matter would suffer from frost ... proteins is one of the major evolutionary routes taken by ...
... a comprehensive, open-access collection of georeferenced biological information about ... refers to the visible-for-the-eye organisms that live near or ... sponges , ascidians , crustaceans . ... conservation activities on species living near the ocean bottom ...
... that has emerged in the Middle East is well-adapted to ... to a study to be published on February 19 in ... Society for Microbiology. The study indicates that the virus HCoV-EMC ... and evade the innate immune system as easily as a ...
Cached Biology News:Not just cars, but living organisms need antifreeze to survive 2Not just cars, but living organisms need antifreeze to survive 3Data paper describes Antarctic biodiversity data gathered by 90 expeditions since 1956 2Data paper describes Antarctic biodiversity data gathered by 90 expeditions since 1956 3Novel coronavirus well-adapted to humans, susceptible to immunotherapy 2Novel coronavirus well-adapted to humans, susceptible to immunotherapy 3
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: